HOME >> BIOLOGY >> NEWS
Clemson researcher receives Komen grant

CLEMSON A Clemson University scientist has received $250,000 to pursue a promising line of research for a way to treat breast cancer. Wen Y. Chen, associate professor in Clemson's department of biological sciences and assistant director of the Oncology Research Institute of Greenville Hospital System, has received funding from the prestigious Susan G. Komen Breast Cancer Foundation in Dallas. He is the first scientist from South Carolina to receive a Komen Foundation grant. Chen will use the money to further his research on stopping breast cancer cells from developing.

"We are excited and grateful for this grant," said Chen. "It signals that we are on the right track. In the past five years, we have focused on developing a potential treatment for breast cancer. With this grant we can move ahead on testing whether the combination approach will significantly improve the existing treatment in an aggressive subtype of breast cancer."

Scientists have learned that human prolactin (PRL), a hormone normally produced in the brain and mainly responsible for mammary gland development and milk production, may be involved in breast cancer development.

"The involvement of PRL in breast cancer is likely due to, in some cases, the fact that mutated breast cells produce PRL as their own survival-growth factor, which keeps most growth signal at "on" position," said Chen. "This self-sustained, vicious growth ability eventually leads to cancer formation."

To "turn off" these growth signals induced by PRL, scientists set out to develop a counteragent -- an antagonist. Working with his colleagues and graduate students at the Oncology Research Institute, Chen has demonstrated that a mutated PRL, called PRL antagonist (G129R), is able to bind specifically to breast cancer cells and block the effect of PRL, inhibiting tumor growth in mice. What's more, the PRL antagonist has synergistic effects with the breast cancer drug Herceptin, which has only 30 percent response
'"/>

Contact: Wen Y. Chen
wenc@clemson.edu
864-455-1457
Clemson University
28-May-2004


Page: 1 2

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Clemson researcher places hope on pushy photons
3. Clemson University researcher reaches for the stars to prevent osteoporosis
4. Clemson launches S.C. DNA Learning Center
5. Clemson dedicates biotech research complex
6. Breakthrough Clemson research appears in Science
7. Clemson researcher takes part in breakthrough research on insects
8. Clemson researchers find bacteria fighter that does not promote bacterial resistance
9. Clemson researchers identify mental retardation gene
10. Clemson researchers create biosensors to protect nations food and water supplies
11. Clemson-led team makes breakthrough in controlling Bt resistance in pests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Over the ... into their drug discovery research workflows with biology ranging from single cell-type spheroids ... of in vitro studies, they create several challenges that need to be overcome ...
(Date:12/27/2018)... FRANCISCO (PRWEB) , ... December 27, 2018 , ... ... annual Microbiome Conference at JPM as part of the JP Morgan 37th Annual ... innovative scientists and physicians, and members of the investment community. , Since ...
(Date:12/20/2018)... ... December 20, 2018 , ... Human Factors and product ... a new usability/observation room. This addition will help meet the increased industry demand ... delivery devices/combination products are safe and easy to use when released to the ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... Fla. (PRWEB) , ... January ... ... Geometrical Implant Co, (SAGICO), an innovative spinal implant company, announced today that ... in San Francisco, California. The annual J.P. Morgan Healthcare Conference is ...
(Date:1/7/2019)... SEONGNAM, South Korea (PRWEB) , ... January 07, ... ... has completed Phase 1 clinical trials of its Parkinson's Disease drug candidate, code-named ... disease-modifying treatment of Parkinson's Disease. The trial took place in South Korea. ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, Inc., ... today announced the founding of a scientific and medical advisory board (SMAB). The ... leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT ... emerging biosciences ventures invited to participate in the annual program. Twelve ventures will ... plans and a professional network. All startups receive an entrepreneur coach, access to ...
Breaking Biology Technology:
Cached News: